CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 93 enrolled
Drug / intervention
androgen oxandrolone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00348946
NCT00348946Phase 2Completed
CompareCT.gov

Androgen Effect on Motor/Cognitive Outcome in Klinefelter Syndrome

Thomas Jefferson University·interventional·Posted Jul 6, 2006·Updated Jul 8, 2021

In Brief

A Phase 2 clinical trial evaluating androgen oxandrolone and placebo for Klinefelter Syndrome. Completed, enrolled 93 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effects of low-dose androgen on the motor and cognitive development of boys with Klinefelter syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKlinefelter Syndrome
CountriesUnited States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 6, 2006
Enrollment StartJul 1, 2006
Primary CompletionNov 30, 2017
TodayJul 2, 2026
Enrollment to primary: 11.4 yearsPosted 20.0 years ago

Interventions

androgen oxandrolonedrug

Oxandrolone ,06 \>mg/kg/day, orally, for 2 years

placeboother

an inactive substance